Akero Therapeutics AKRO 深 沪
等待开盘 04-02 09:30:00 美东时间
54.65
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 54.65
- 总市值 44.99亿
- 52周最高 58.40
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 21.34
- 委 比 0.00%
- 总股本 8231.62万
- 历史最高 58.40
- 量 比 0
- 振 幅 0.00%
- 历史最低 7.52
- 每 手 1
- 风险率 5.63%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cantor Fitzgerald Suspends Overweight Rating on Akero Therapeutics
Cantor Fitzgerald suspends Overweight rating on Akero Therapeutics (NASDAQ:AKRO).
2025-12-10 21:56
Akero Therapeutics Announces Merger and Delisting Plans
Akero Therapeutics ( ($AKRO) ) has provided an update. On December 9, 2025, Ake...
2025-12-09 22:27
BRIEF-Novo Nordisk Completes Acquisition Of Akero Therapeutics
Dec 9 (Reuters) - Novo Nordisk A/S NOVOb.CO: HAS COMPLETED ITS ACQUISITION OF AKERO THERAPEUTICS BUYS AKERO FOR $4.7 BILLION COMMON STOCK OF AKERO WILL NO LONGER BE LISTED OR TRADED ON NASDAQ GLOBAL S...
2025-12-09 21:53
BRIEF-Akero Therapeutics Stockholders Approve Acquisition By Novo Nordisk
Dec 3 (Reuters) - Akero Therapeutics Inc AKRO.O: AKERO THERAPEUTICS INC - STOCKHOLDERS APPROVE ACQUISITION BY NOVO NORDISK - SEC FILING Source text: [ID:n0001140361-25-044131] Further company coverage...
2025-12-03 23:50
Akero Therapeutics Inc. Held Special Shareholder Meeting
Akero Therapeutics Inc. held a special meeting of stockholders on December 2, 2025. At the meeting, stockholders approved the proposed acquisition of Akero Therapeutics Inc. by Novo Nordisk A/S, inclu...
2025-12-03 23:42
Akero Therapeutics Highlights New Data Showing Liver Fibrosis Reversal in MASH Patients
Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced new findings from
2025-11-07 20:07
Akero Therapeutics Reports Efruxifermin Shows Antifibrotic Activity in 96-Week MASH Trials
Akero Therapeutics Inc. announced new findings from its Phase 2b SYMMETRY and HARMONY trials evaluating efruxifermin in patients with metabolic dysfunction-associated steatohepatitis (MASH), including...
2025-11-07 20:00
MNC半年豪掷107亿美元，这个脂肪肝靶点终于爆了
文 | 医曜 早在2023年底的时候，我们就曾推断：脂肪肝将是减肥药后的下一个千亿战场。如今MNC正用真金白银，让这一推断渐渐落地。 10月9日，诺和诺德突然...
2025-10-18 12:37
Novo Nordisk, Eli Lilly slide after Trump pledges 'much lower' Ozempic price
Danish drugmaker Novo Nordisk (NVO) slipped 6% in early trading on Friday after U.S. President Donald Trump said on Thursday that the price of the company's top-selling weight-loss medication would be...
2025-10-17 16:05
